In the four years since joining the GAP Program, the Moldova Hemophilia Society (MHS) has made significant steps forward in advancing hemophilia care within the country. One of the main achievements is a recent significant increase in the purchase of life-saving clotting factor concentrates (CFCs).
Earlier this year, the Ministry of Health of the Republic of Moldova carried out the 2014 year tender and 1.2 IUs/per capita of FVIII and FIX were purchased; this means that the initial GAP target of 0.65 IUs/per capita was doubled. The amount of CFCs purchased in 2014 exceeds the CFC supply in the first year of GAP program (2011) by about eight times.
A major step forward in the treatment of hemophilia B in Moldova came in 2013 when the Ministry of Health purchased FIX for the first time.
Another important achievement of the GAP Program is enhancing the medical expertise by providing both in-country and international training opportunities for members of the hemophilia care team at the pediatric and adult hemophilia training centres (HTC) in Chisinau. Both HTCs also have internationally trained physiotherapists and in 2013 the WFH purchased physiotherapy equipment for both centres so that they can now offer better physiotherapy services to patients with bleeding disorders.
In March 2014, the WFH and MHS organized a one-day conference on hemophilia treatment with Dr. Jerzy Windyga from Poland leading several interesting discussions. Around 40 participants took part in the conference including medical professionals, patients with hemophilia and their family members.
The Moldovan Hemophilia Society has also created a computerized national patient registry, which will be managed by the Chisinau HTC.
The WFH is grateful for the support of the GAP Program from Baxter, Bayer, Biogen Idec Hemophilia, Biotest, CSL Behring, Grifols, Kedrion, Novo Nordisk, Pfizer, and SOBI.